• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Transl Med . Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudovir

tetano

Editor, Senior Moderator
Sci Transl Med


. 2022 Jan 13;eabn7842.
doi: 10.1126/scitranslmed.abn7842. Online ahead of print.
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses


Benjamin L Sievers[SUP] #[/SUP][SUP] 1 [/SUP], Saborni Chakraborty[SUP] #[/SUP][SUP] 2 [/SUP], Yong Xue[SUP] #[/SUP][SUP] 1 [/SUP], Terri Gelbart[SUP] #[/SUP][SUP] 1 [/SUP], Joseph C Gonzalez[SUP] 2 3 [/SUP], Arianna G Cassidy[SUP] 4 [/SUP], Yarden Golan[SUP] 5 [/SUP], Mary Prahl[SUP] 6 [/SUP], Stephanie L Gaw[SUP] 4 [/SUP], Prabhu S Arunachalam[SUP] 7 [/SUP], Catherine A Blish[SUP] 2 3 8 [/SUP], Scott D Boyd[SUP] 9 10 [/SUP], Mark M Davis[SUP] 7 11 12 [/SUP], Prasanna Jagannathan[SUP] 2 11 [/SUP], Kari C Nadeau[SUP] 10 [/SUP], Bali Pulendran[SUP] 7 [/SUP], Upinder Singh[SUP] 2 11 [/SUP], Richard H Scheuermann[SUP] 1 [/SUP], Matthew B Frieman[SUP] 13 [/SUP], Sanjay Vashee[SUP] #[/SUP][SUP] 1 [/SUP], Taia T Wang[SUP] #[/SUP][SUP] 2 3 11 8 [/SUP], Gene S Tan[SUP] #[/SUP][SUP] 1 14 [/SUP]



Affiliations

Abstract

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that possess mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by pre-existing immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wildtype (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.
 
Back
Top Bottom